吉西他滨联合奥沙利铂治疗进展期胰腺癌

目的:本研究观察了吉西他滨(健择)联合奥沙利铂(艾恒)组成GO方案治疗进展期胰腺癌的有效性及安全性。方法:自2004年1月~2006年1月,30例进展期胰腺癌患者接受GO方案治疗。GO方案:健择800mg/m2,静脉滴入第1,第8天,艾恒60 mg/m2第2第9天,28天为1个周期,共进行6周期,所有患者均接受了至少2个周期的治疗。结果:30例患者平均年龄62岁,所有患者共进行了99周期治疗,平均每个患者接受3.3周期治疗。30例患者中PR 6例,SD11例,PD13例,总有效率为20%,TCR为56.7%。中位进展时间4.37个月,中位生存时间7.14个月,一年生存率为20%。临床受益率显著,CBR达73.3%。具有较好的耐受性,主要毒副反应是血液学毒性。结论:健择联合艾恒治疗进展期胰腺癌疗效较好,毒副反应可以耐受。

Gemcitabine and Oxaliplatin in Treatment of Advanced Pancreatic Cancer

Objective:In the present phase II multicenter study,we assessed the efficacy and tolerability of the combination of gemcitabine and oxaliplatin in patients with advanced pancreatic cancer.Methods:Patients with previously untreated,locally advanced or metastatic pancreatic cancer were treated with gemcitabine 800 mg/m2 on days 1 and 8 and oxaliplatin 60 mg/m2 on day 2 and 9 of a 4-week cycle,for a total of six cycles.All patients received over two cycles of this regimen.Results:A total of 30 patients were enrolled in the study.The median age was 62 years(range 35-72).A total of 98 cycles were administered.Mean cycle number per patient was 3.3.Among 30 patients evaluable for response,6(20%)achieved partial response;11(36.7%)and 13(43.3%)patients had stable and progressive disease,respectively.The median overall survival was 7.14 months;the median TTP was 4.37 months and the 1-year survival was 20%.The observed clinical benefit response was remarkable.The most common grade 3-4 toxicities were hematological,including 3% anemia,13% neutropenia and 12% thrombocytopenia.Conclusions:The combination of gemcitabine plus oxaliplatin is a moderately active treatment for patients with locally advanced and metastatic pancreatic cancer.This regimen has an acceptable toxicity profile and provides a significant clinical benefit,and hence warrants further investigation.